Evidence map›Paper›PMID 39549747›Full record

ArticleMolecules and cells2024

Single-molecule FRET-based approach for protein-targeted drug discovery.

Yuyoung Kim, Surim Kim, Kang Heo, Sanghwa Lee

Abstract read
In one paragraph

Article in Molecules and cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuyoung KimDepartment of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea; Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul 06591, Republic of Korea.
Surim KimDepartment of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea; Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul 06591, Republic of Korea.
Kang HeoStrategic Development Team, Vieworks Company, Anyang-si, Gyeonggi-do 14055, Republic of Korea.
Sanghwa LeeDepartment of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea; Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul 06591, Republic of Korea. Electronic address: sanghwalee@catholic.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many therapeutic drugs target various proteins involved in diverse biological processes. Among these proteins, type II topoisomerases are critical targets for anticancer and antibacterial chemotherapies, yet the action mechanisms of many type II topoisomerase-targeting drugs have not been fully elucidated. In this regard, the development of rapid and accurate methods to identify the mode of action of potential drug candidates is crucial to improve the efficiency of drug screening and discovery. Here, using type II topoisomerase as a model system, we present a single-molecule fluorescence resonance energy transfer-based drug screening method capable of delineating when and how the drug candidates participate in the entire reaction steps of the target protein. This unique capability has been demonstrated to be applicable to the identification of representative types of widely prescribed drugs targeting type II topoisomerase: etoposide which stabilizes the enzyme-DNA cleavage complex, and bisdioxopiperazines (ICRF-I93) which lock the N-terminal gate of the enzyme into the closed state. Based on this demonstration experiment, we expect that our proposed method will be extended to broad applications in the screening of potent drugs targeting various proteins.

Indexed as

DNA Topoisomerases, Type IIDrug DiscoveryFluorescence Resonance Energy TransferEtoposideHumansSingle Molecule ImagingTopoisomerase II InhibitorsDNA Topoisomerases, Type IIEtoposideTopoisomerase II InhibitorsBisdioxopiperazinesDrug screeningEtoposideSingle-molecule fluorescence resonance energy transferType II topoisomerase

Identifiers

PMID39549747
PMCPMC11667156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.